# Reviva Pharmaceuticals Holdings, Inc.

Reviva Pharmaceuticals Holdings, Inc. is an Asset Manager based in San Jose, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** San Jose, United States
- **Region:** North America
- **Address:** San Jose, CA, United States
- **Founded:** 2006
- **Assets under management:** Undisclosed
- **Website:** revivapharma.com

## Regulatory record

- **Reports private funds:** No

## About

Reviva Pharmaceuticals was founded in 2006 by Laxminarayan Bhat, who had previously served as a scientist at companies including Johnson & Johnson and TransForm Pharmaceuticals. The company focuses on discovering and developing small-molecule therapies for neuropsychiatric and inflammatory disorders. Its pipeline is anchored by brilaroxazine (RP5063), a novel serotonin-dopamine stabilizer that has completed a Phase 3 trial for schizophrenia (per ClinicalTrials.gov, 2024). The drug showed statistically significant improvement in PANSS score versus placebo at four weeks. Additional preclinical programs target Rett syndrome, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. The company's strategy involves licensing or partnering late-stage assets with larger pharmaceutical firms rather than building a commercial infrastructure. Reviva went public via a reverse merger with BioCorRx in 2020, and its shares trade on the NASDAQ under the ticker RVPH. The firm reported a cash position of about $17.5 million as of September 30, 2023 (per SEC filing), funding operations through a combination of equity offerings and a $10 million registered direct offering in November 2023 (per SEC filing). It has no disclosed AUM or family-office backing. Reviva is structurally a development-stage public biotech, not a family office, investment firm, or asset manager. Its distinguishing feature is an outsourced-commercialization model, aiming to license its pipeline to partners with existing sales forces rather than building its own commercial operations.

## Sectors

- Biotech
- Pharmaceuticals
- Healthcare Services

## People

- Laxminarayan Bhat — Founder, CEO and President
- Vimal Kavuru — Chief Financial Officer

## Questions

### Who leads investment decisions at Reviva Pharmaceuticals?

Laxminarayan Bhat, as founder, CEO, and President, directs corporate strategy and pipeline investment decisions. The firm is a public company with board oversight; key decisions on financing, partnerships, and capital allocation are made by Bhat and the executive team, subject to board approval (per SEC filings).

### What is the current status of Reviva's lead drug candidate?

Brilaroxazine (RP5063) completed a Phase 3 trial for schizophrenia in 2024, meeting its primary endpoint at four weeks. The company plans to file a New Drug Application with the FDA after completing long-term safety studies (per ClinicalTrials.gov, 2024).

### How is Reviva funded?

The firm funds operations through public equity offerings, including a $10 million registered direct offering in November 2023, and potential partnership/licensing milestones. It has not disclosed venture-capital or family-office backing (per SEC filings).

### Does Reviva have a track record of partnerships for its pipeline?

As of 2024, Reviva has not announced a licensing or co-development deal for brilaroxazine. The company states its strategy is to partner late-stage assets with larger pharmaceutical companies for commercialization, but no such agreement has been publicly disclosed.

## Related profiles

- [Northern Minerals & Exploration Ltd.](https://altss.com/profile/northern-minerals-and-exploration-ltd)
- [E-Home Household Service Holdings Ltd](https://altss.com/profile/e-home-household-service-holdings-ltd)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/reviva-pharmaceuticals-holdings-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology